This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Infliximab

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Infliximab is a chimeric humanised mouse anti-TNF monoclonal antibody, that binds to and inhibits human TNF-alpha.

It has been used in the treatment for acute Crohn's disease, but was primarily designed for the treatment of rheumatoid arthritis.

It is given by intravenous infusion at 0,2 and 6 weeks then every 8 weeks thereafter. It is licensed for concomitant use with Methotrexate in adults with RA responding inadequately to DMARDs including methotrexate.

Check the Summary of Product Characteristics before prescribing this drug.


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.